Introduction
============

Epithelial ovarian cancer (EOC) is the most common type of invasive ovarian cancer, and a leading cause of cancer-associated mortalities in females globally ([@b1-ol-0-0-8130],[@b2-ol-0-0-8130]). In China, the incidence rate of ovarian cancer was 7.91/100,000 and the age-adjusted incidence rate was 5.35/100,000 between 1999 and 2010 ([@b3-ol-0-0-8130]). The incidence of EOC increases rapidly following menopause ([@b4-ol-0-0-8130]). Although a number of factors are involved the in the molecular mechanism behind EOC, these risk factors are not well defined and the pathogenesis of EOC remains unclear ([@b5-ol-0-0-8130]). The progress in the treatment of EOC is not optimistic, the prognosis is poor and the 5-year relative survival rate is \~30% ([@b6-ol-0-0-8130]).

In recent years the functions of microRNAs (miRNAs/miRs) in the cancer have begun to be revealed ([@b7-ol-0-0-8130]--[@b12-ol-0-0-8130]), and a number of miRNAs have been identified to be involved in the pathogenesis of EOC ([@b13-ol-0-0-8130]--[@b19-ol-0-0-8130]). miRNAs are evolutionarily conserved, small non-coding RNAs that regulate the expression of genes and translocation of proteins ([@b20-ol-0-0-8130]).

The functions of miR-545 have been studied in several types of cancer. In pancreatic ductal adenocarcinoma, miR-545 inhibited cellular proliferation and was associated with a decreased survival rate in patients ([@b21-ol-0-0-8130]). In lung cancer, miR-545 suppressed cellular proliferation via the inhibition of cyclin D1 and cyclin-dependent kinase 4 expression ([@b22-ol-0-0-8130]). However, the function of miR-545 in EOC remains unknown.

In the present study, the expression level of miR-545 was analyzed in EOC tissues and the *in vitro* functions of miR-545 were investigated. Subsequently, the potential miR-545-target genes were assessed.

Materials and methods
=====================

### Patients and tissues

A total of 27 EOC tissues and matched normal adjacent tissues were collected from 27 subjects (the mean age was 59.9 years, and the range was 36--45 years) who underwent surgery for the treatment of EOC at the West China Women\'s and Children\'s Hospital of Sichuan University (Chengdu, China). The histopathological diagnosis of EOC was provided and confirmed by the senior pathologist of the West China Second University Hospital, Sichuan University (Chengdu, Sichuan 610041). The survival status of patients was recorded and used for Kaplan-Meier survival analysis. Patient information is summarized in [Table I](#tI-ol-0-0-8130){ref-type="table"}. The present study was approved by Ethic Committee of Sichuan University and each patient provided written informed consent.

### Cell lines

The EOC SKOV3 and HO8910 cell lines and the normal immortalized human ovarian surface epithelial cells IOSE29 were acquired from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI-1640 medium with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) ([@b23-ol-0-0-8130]).

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Following cell and tissue isolation, total RNA was purified from EOC tissues, IOSE29, SKOV3, HO8910 cell lines (treated or control group) using TRIzol reagent (Life Sciences; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The extracted RNA was dissolved in DEPC-treated ddH~2~O and subjected to DNAse I treatment (catalog no, EN0521; Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA was reverse-transcribed to cDNA by using All-in-One^™^ miRNA First-Strand cDNA Synthesis kit (catalog no. AMRT-0020; Biocompare, South San Francisco, CA, USA). The PCR process was completed by SYBR^®^ Green PCR Master Mix (catalog no. 4364344; Thermo Fisher Scientific, Inc.). The primers were synthesized and tested by the Chengdu Haoyi Biotechnology Co., Ltd (<http://haoyibio.net>) (Chengdu, China). The following primers were used for the analysis: miR-545, 5S rRNA forward primer, 5′-ACGGCCATACCACCCTGAAC-3′, reverse primer, 5′-GGCGGTCTCCCATCCAAGTA-3′; U6 forward primer, 5′-CTCGCTTCGGCAGCACA-3′, reverse primer, 5′-AACGCTTCACGAATTTGCGT-3′. Data analysis were performed using the the 2^−ΔΔCq^ method of normalization ([@b24-ol-0-0-8130]). U6 was used for the normalization of miR-545 ([@b10-ol-0-0-8130],[@b25-ol-0-0-8130]--[@b27-ol-0-0-8130]).

### miR-545 mimics and anti-sense oligonucleotides transfection (ASO)

The miR-545 mimics (5′-UCAGCAAACAUUUAUUGUGUGC-3′), miR-545 ASO (5′-GCACACAAUAAAUGUUUGCUGA-3′) and negative controls (5′-UGGGCGUAUAGACGUGUUACAC-3′) were purchased from Dharmacon (GE Healthcare Life Sciences, Little Chalfont, UK). Cells were seeded at 2×10^5^ per well in 6-well plates for further investigation. These cells were transfected with miR-545 mimics, miR-545 ASO or miR-545 mimics using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. After 24 h, the transfected cells were used for further experiments.

### Cell proliferation assay

The cellular proliferation was assessed using an MTT assay. SKOV3 and HO8910 cells were seeded into 96-well plates at a density of 5×10^5^ cells/well. MTT reagent was added into the medium at a final concentration of 0.1 mg/ml and the plate was incubated at 37°C for 3 h. Following incubation, Dimethyl sulfoxide (100 µl) was added at 37°C for 15 min. Optical density was measured using a microplate reader at 570 nm.

### Cell apoptosis analysis

Annexin V-fluorescein isothiocyanate (FITC) Staining/Detection kit (ab14085, Abcam, Cambridge, UK) was used. The binding buffer were prepared according to the manufacturer\'s protocol. Treated SKOV3 and HO8910 cells were suspended (5×10^5^ cells/ml) in 1xbinding buffer. Annexin V-FITC (5 µl) was added and incubated for 15 min at room temperature. Subsequently, propidium iodide (5 µl) (ab14083, Abcam) was added for 5 min at room temperature, samples were analyzed with a flow cytometer using the 488 nm excitation line (Argon-ion laser or solid state laser) and emission detected at 530 nm (green, FITC) and 575--610 nm (orange, PI). The data was analyzed by BD LSR II software (v.1.1.0, Franklin, NJ, USA).

### Dual luciferase reporter assays

SKOV3 cells were seeded at 1×10^5^ per well and were serum-starved for 6 h prior to transfection. The RAC-γ serine/threonine-protein kinase (AKT3) 3′-UTR reporter plasmid (500 ng) and the pGL3-control (100 ng) (Promega Corporation, Madison, WI, USA) were co-transfected into cells using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Cells were harvested and luciferase activities were analyzed after 24 h using the Dual-Luciferase Reporter Assay system (Promega Corporation). Mutants of AKT3 3′-UTR were generated using a Site-Directed Mutagenesis kit (Promega Corporation). The data was normalized by Renilla luciferase activity. The value in miR-NC group was arbitrarily defined as 100%.

### Prediction of the possible targets of miR-545

Targetscan software (<http://www.targetscan.org/>) was used to predict the possible targets of miR-545 by searching miR-545. TargetScan is online software, that predicts biological targets of miRNA by searching for the presence of conserved 8mer, 7mer, and 6mer sites that match the seed region of each miRNA ([@b28-ol-0-0-8130]).

### Western blot analysis

The lysates were prepared with lysis buffer (M-PER™ Mammalian Protein Extraction Reagent, Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing protease inhibitors (Pierce Protease Inhibitor, A32963, Thermo Fisher Scientific, Inc.) and then were cleared by centrifugation. The protein concentration was assayed by Pierce^™^ Rapid Gold BCA Protein Assay Kit (Thermo Fisher Scientific, Inc.). Total proteins (30 µg) were resolved using SDS-PAGE (10%) and transferred onto polyvinylidene difluoride membranes (Merck KGaA, Darmstadt, Germany). The membranes were immersed with 5% non-fat dry milk (in Blocking Buffer, Thermo Fisher Scientific, Inc.) for 15 min at room temperature. Membranes were washed with PBS for 15 min and then incubated with primary antibodies overnight in 4°C, washed by PBS for three times. Then the membranes were incubated with secondary antibodies for 2 h at room temperature. Western blot Signal was developed by Pierce™ DAB Substrate Kit (Thermo Fisher, Scientific, Inc.), then the blotting images were captured using CL-XPosure^™^ film 5×7 inch (Thermo Fisher Scientific, Inc.). The following antibodies were used as follows: AKT3 (catalog no. sc-56878, 1:1,000 dilution; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), GAPDH (catalog no. sc69778, 1:3,000 dilution; Santa Cruz Biotechnology, Inc.), goat anti-rabbit (catalog no. sc-2004, 1:10,000 dilution; Santa Cruz Biotechnology, Inc.).

### Statistical analysis

Data are presented as mean ± standard deviation. Statistical analysis was performed using SPSS software (version 10; SPSS, Inc., Chicago, IL, USA). The difference between two groups was analyzed using a two-tailed Student\'s t-test. One-way analysis of variance (ANOVA) was used to analyze the difference between three groups; Fisher\'s least significant difference test was performed following ANOVA. Analysis of the survival rate of patients with EOC was performed via Kaplan-Meier survival curves and a log-rank test was performed to confirm the significance. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### miR-545 expression is decreased in EOC tissues and low level of miR-545 is associated with low survival rate of patients with EOC

The miR-545 levels in 27 EOC tissues samples were analyzed using RT-qPCR. The levels of miR-545 expression were decreased in tumor tissues compared with matched-adjacent normal tissues in 23 specimens ([Fig. 1A](#f1-ol-0-0-8130){ref-type="fig"}). The mean expression of miR-545 in the 27 EOC tissues samples was significantly lower than that in the adjacent normal samples ([Fig. 1B](#f1-ol-0-0-8130){ref-type="fig"}). The survival rate of the patients for 66 months following surgical treatment was also assessed, and the 27 patients with EOC were divided into two groups according to the median value of the miR-545 expression in EOC tissues. Kaplan-Meyer survival analysis revealed that patients expressing increased levels of miR-545 in EOC tissues were associated with increased survival rates ([Fig. 1C](#f1-ol-0-0-8130){ref-type="fig"}).

### Overexpression of miR-545 inhibits cells growth and promotes apoptosis

Next the function of miR-545 in the EOC cell lines SKOV3 and HO8910 was tested. It was identified that miR-545 was expressed at decreased levels in SKOV3 and HO8910 cells compared with normal ovarian tissue and the normal immortalized human ovarian surface epithelial cells IOSE29 ([Fig. 2A](#f2-ol-0-0-8130){ref-type="fig"}). Next the miR-545 levels in SKOV3 and HO8910 cells were determined following transfection with miR-545 mimics; miR-545 mimics upregulated the miR-545 levels in the two cell lines at 48 and 72 h after transfection ([Fig. 2B](#f2-ol-0-0-8130){ref-type="fig"}). Cellular proliferation and apoptosis were assessed using MTT analysis at 48 h after transfection with miR-545 mimics or the negative control. Overexpression of miR-545 was revealed to inhibit cellular proliferation ([Fig. 2C](#f2-ol-0-0-8130){ref-type="fig"}). At 48 h after transfection, the rates of cell apoptosis were assessed using flow cytometry, and it was identified that miR-545 increased the apoptosis rate in SKOV3 and HO8910 ([Fig. 2D](#f2-ol-0-0-8130){ref-type="fig"}).

### Suppression of miR-545 promoted cell proliferation and inhibited apoptosis

The miR-545 levels in SKOV3 and HO8910 were suppressed by miR-545 ASO transfection. After 48 and 72 h, the miR-545 levels were assayed using RT-qPCR. It was identified that miR-545 ASO significantly suppressed the miR-545 levels at the two time points ([Fig. 3A](#f3-ol-0-0-8130){ref-type="fig"}). The MTT assay revealed that miR-545 ASO transfection promoted cellular proliferation in SKOV3 and HO8910 cells ([Fig. 3B](#f3-ol-0-0-8130){ref-type="fig"}). Similarly, 48 h after transfection, the cell apoptosis rates were assessed using FACS analysis, and it was revealed that miR-545 ASO decreased the apoptosis rate in SKOV3 and HO8910 cells ([Fig. 3C](#f3-ol-0-0-8130){ref-type="fig"}).

### AKT3 is targeted by miR-545

The phosphatidylinositol 3-kinase (PI3K)/AKT pathway has been demonstrated to serve a function in oncogenic transformation in ovarian cancer, with AKT3 being an important mediator of ovarian oncogenesis ([@b29-ol-0-0-8130]). The bioinformatics algorithm suggested that miR-545 may bind the 3′-UTR of AKT3 ([Fig. 4A](#f4-ol-0-0-8130){ref-type="fig"}). The intact 3′-UTR of AKT3 and its mutated version were cloned into luciferase reporter plasmids and used for co-transfection with miR-545 into IOSE29 cells. It was revealed that miR-545 decreased the luciferase activity of the wild type 3′-UTR reporter, whereas the luciferase activity of the reporter with the mutated version was not significantly different between miR-NC and miR-545 ([Fig. 4B](#f4-ol-0-0-8130){ref-type="fig"}). At 48 h after transfection of the miR-545 mimics into the SKOV3 cells, AKT3 protein levels in the SKOV3 cells were assayed by western blot analysis, and found that these data indicated that miR-545 exerted its function through AKT3. Transfected miR-545 mimics decreased the AKT3 protein levels ([Fig. 4C](#f4-ol-0-0-8130){ref-type="fig"}).

Discussion
==========

miRNAs have been demonstrated to be involved in the pathogenesis of EOC ([@b30-ol-0-0-8130]--[@b32-ol-0-0-8130]). A previous study by the authors revealed the function of miR-494 in EOC ([@b33-ol-0-0-8130]). The authors demonstrated that miR-494 was expressed at low levels in EOC tissues and cells. Overexpression of miR-494 inhibited the proliferation and migration of the EOC cells. miR-494 was revealed to target Myc proto-oncogene protein ([@b34-ol-0-0-8130]). In the present study, the function of miR-545 in EOC was analyzed and it was demonstrated that miR-545 served an antitumor function, and AKT3 was targeted by miR-545.

miR-545 appears to function as a cancer suppressor gene in a number of types of cancer, including pancreatic ductal adenocarcinoma and lung cancer ([@b22-ol-0-0-8130],[@b35-ol-0-0-8130]). In a previous study, inhibition of miR-545 expression decreased the radiosensitivity of Lewis lung carcinoma, with miR-545 regulating Ku70 expression by targeting the 3′-UTR of Ku70, a process that was involved in radiotherapy ([@b36-ol-0-0-8130]). On the one hand, miR-545 can inhibit the proliferation of cancer cells by targeting oncogenes ([@b35-ol-0-0-8130]); however, miR-545 could also enhance radiosensitivity during cancer therapy. Thus, miR-545 is a good candidate target for cancer therapy.

Expression of AKT3 is increased in several types of cancer ([@b37-ol-0-0-8130]). In triple negative breast cancer (TNBC), the downregulation of AKT3 inhibits the cellular proliferation of TNBC cell lines and depletion of AKT3 in TNBC sensitizes cells to the pan-AKT inhibitor GSK690693 ([@b38-ol-0-0-8130]). Additionally, in prostate cancer, AKT3 promotes the proliferation of prostate cancer proliferation cells through regulation of AKT, serine/threonine protein kinase B-Raf and tuberous sclerosis 1/2 ([@b39-ol-0-0-8130]).

In conclusion, the data collected in the present study demonstrated that miR-545 may serve an antitumor function in EOC.
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![Low levels of miR-545 in EOC tissues are associated with low survival rates of patients with EOC. (A) Reverse transcription-quantitative polymerase chain reaction experiments were performed to assess the expression of miR-545 in EOC tissues. U6 small nuclear RNA was used as blank control. The values are relative to the expression of miR-545 \[log2 (Tumor/Normal)\]. (B) The mean value of miR-545 levels in EOC tissues and the adjacent normal tissues were calculated. (C) The median values of miR-545 expression in 27 EOC tissues was used as the cutoff point separating miR-545-high-expression group (n=13) from the miR-545-low-expression group (n=13). A Kaplan-Meier survival curve was produced. The data are presented as the mean ± standard deviation. The same experiment was repeated at least three times. \*P\<0.05. miR-545, microRNA-545; EOC, epithelial ovarian cancer.](ol-15-05-6386-g00){#f1-ol-0-0-8130}

![Transfection of miR-545 mimics inhibits cell growth and promotes apoptosis. (A) The miR-545 levels in normal ovarian tissues; IOSE29, SKOV3 and HO8910 cells were analyzed using RT-qPCR. The miR-545 level in normal ovarian tissues was arbitrarily defined as 100%. (B) miR-545 mimics were transfected into SKOV3 and HO8910, and after 48 and 72 h the miR-545 levels were analyzed using RT-qPCR. Levels of miR-545 expression in normal ovarian tissues was arbitrarily defined as 100%. (C) Following transfection with miR-NC or miR-545 mimic, cellular proliferation was analyzed using an MTT assay at 24, 48 and 72 h, (D) At 48 h after transfection with the miR-545 mimic, cell apoptosis was measured using annexin V-propidium iodide staining. Data are presented as the mean ± standard deviation. The experiment was repeated at least three times. \*P\<0.05 vs. NC. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; miR-545, microRNA-545; OD, optical density; NC, negative control.](ol-15-05-6386-g01){#f2-ol-0-0-8130}

![Transfection of miR-545 ASO promotes cell growth and inhibits apoptosis. (A) miR-545 ASO were transfected into SKOV3 and HO8910 cells, and 48 and 72 h later, the miR-545 levels were analyzed by reverse transcription-quantitative polymerase chain reaction. The miR-545 level in normal ovarian tissues was arbitrarily defined as 100%. (B) At 24, 48 and 72 h after transfection with miR-NC ASO or miR-545 mimic ASO, the cellular proliferation was analyzed using an MTT assay. (C) The cell apoptosis was measured using annexin V-propidium iodide staining 48 h after miR-545 ASO transfection. The data are the mean ± standard deviation. The experiment was repeated at least three times. \*P\<0.05 vs. NC. miR-545, microRNA-545; anti-sense oligonucleotides ASO; OD, optical density; NC, negative control.](ol-15-05-6386-g02){#f3-ol-0-0-8130}

![AKT3 is targeted by miR-545. (A) The binding site and its mutated sequence are presented, and the mutated sites are annotated. (B) miR-545 inhibited the activity of luciferase containing the 3′-UTR of the AKT3 gene and did not inhibit the mutated version. (C) SKOV3 cells were transfected with miR-545 mimics and 48 h later, the abundance of AKT3 protein was assessed using western blotting. The experiment was repeated at least three times. \*P\<0.05. miR-545, microRNA-545; WT, wild type; AKT3, RAC-γ serine/threonine-protein kinase; 3′-UTR, 3′-untranslated region; NC, negative control.](ol-15-05-6386-g03){#f4-ol-0-0-8130}

###### 

Characteristics of patients with ovarian cancer.

  No.   Age, years   Type                               Stage   Follow-up time, months   Status
  ----- ------------ ---------------------------------- ------- ------------------------ ----------
    1   45           Epithelial ovarian cancer/serous   IV      34                       Deceased
    2   54           Epithelial ovarian cancer/serous   IV      44                       Deceased
    3   46           Epithelial ovarian cancer/serous   III     55                       Deceased
    4   56           Epithelial ovarian cancer/serous   III     66                       Survived
    5   48           Epithelial ovarian cancer/serous   IV      66                       Survived
    6   36           Epithelial ovarian cancer/serous   III     66                       Survived
    7   57           Epithelial ovarian cancer/serous   III     66                       Survived
    8   45           Epithelial ovarian cancer/serous   IV      66                       Survived
    9   64           Epithelial ovarian cancer/serous   IV      66                       Survived
  10    75           Epithelial ovarian cancer/serous   IV      66                       Survived
  11    56           Epithelial ovarian cancer/serous   IV      66                       Survived
  12    74           Epithelial ovarian cancer/serous   IV      66                       Survived
  13    69           Epithelial ovarian cancer/serous   IV      66                       Survived
  14    79           Epithelial ovarian cancer/serous   IV        4                      Deceased
  15    75           Epithelial ovarian cancer/serous   IV        7                      Deceased
  16    67           Epithelial ovarian cancer/serous   IV      11                       Deceased
  17    65           Epithelial ovarian cancer/serous   III     13                       Deceased
  18    69           Epithelial ovarian cancer/serous   IV      14                       Deceased
  19    73           Epithelial ovarian cancer/serous   IV      19                       Deceased
  20    65           Epithelial ovarian cancer/serous   IV      22                       Deceased
  21    59           Epithelial ovarian cancer/serous   IV      27                       Deceased
  22    57           Epithelial ovarian cancer/serous   III     66                       Deceased
  23    63           Epithelial ovarian cancer/serous   IV      66                       Survived
  24    67           Epithelial ovarian cancer/serous   IV      66                       Survived
  25    54           Epithelial ovarian cancer/serous   III     66                       Survived
  26    51           Epithelial ovarian cancer/serous   IV      66                       Survived
  27    49           Epithelial ovarian cancer/serous   IV      66                       Survived
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